Abstracts tagged "Cognitive dysfunction"

Abstract Number: 1300 • ACR Convergence 2020
Identifying Cognitive Impairment in Patients with Systemic Lupus Erythematosus Using Hidden Markov Models: A Bayesian Approach
Juan Pablo Diaz-Martinez¹, Kathleen Bingham², Robin Green³, Dorcas Beaton⁴, Mahta Kakvan¹, Lesley Ruttan³, Carmela Tartaglia⁵, Marvin Fritzler⁶, May Choi⁷, Jiandong Su¹, Dennisse Bonilla¹, Nicole Anderson¹, Joan Wither¹, Patricia Katz⁸ and Zahi Touma⁹, ¹University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ⁴Institute for Work & Health, Toronto, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸University of California, San Francisco, Novato, CA, ⁹University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is usually operationalized on the American College of Rheumatology Neuropsychological Battery (ACR-NB) as a z-score of ≤-1.5 on ≥2 domains or…
Abstract Number: 1688 • ACR Convergence 2020
Long-term Hearing Loss, Anxiety and Neurodevelopmental Outcomes Following Kawasaki Disease: A Population-based Cohort Study
Cal Robinson¹, Francis Lao², Rahul Chanchlani¹, Anastasia Gayowsky³, Sandeep Brar⁴, Elizabeth Darling⁵, Catherine Demers⁵, Tapas Mondal¹, Rulan Parekh⁶, Hsien Seow⁵ and Michelle Batthish¹, ¹McMaster Children's Hospital, Hamilton, ON, Canada, ²Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada, ³ICES McMaster, Hamilton, ON, Canada, ⁴University of California, San Fransisco, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Toronto, Toronto, Canada
Background/Purpose: The incidence of Kawasaki disease (KD) is increasing in Ontario. Cardiovascular sequelae following KD are well-described. However, there are limited and conflicting non-cardiovascular outcome…
Abstract Number: 1788 • ACR Convergence 2020
Assessment of the Impact of Interferon Levels on Cognitive Dysfunction in Patients with SLE
Andrew Kwan¹, Joan Wither², Juan Pablo Diaz-Martinez², Robin Green³, Dorcas Beaton⁴, Mahta Kakvan², Lesley Ruttan³, Carmela Tartaglia⁵, Marvin Fritzler⁶, May Choi⁷, Jiandong Su², Dennisse Bonilla², Nicole Anderson², Patricia Katz⁸ and Zahi Touma⁹, ¹University of Toronto, Department of Medicine, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ⁴Institute for Work & Health, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸University of California, San Francisco, Novato, CA, ⁹University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is among the earliest and the most prevalent manifestations of SLE. Previous studies have demonstrated that the increased levels of interferon…
Abstract Number: 1804 • ACR Convergence 2020
Impact of the Kynurenine/Tryptophan Pathway on Cognitive Dysfunction and Depression in Systemic Lupus Erythematosus
Erik Anderson¹, Joanna Fishbein², Joseph Hong², Julien Roeser³, Richard Furie⁴, Cynthia Aranow², Bruce Volpe², Betty Diamond⁵ and Meggan Mackay⁶, ¹Feinstein Institutes for Medical Research, New York, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Charles River Laboratories, South San Francisco, CA, ⁴Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵Northwell Health, Manhasset, NY, ⁶Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Tryptophan (TRP) is metabolized to kynurenine (KYN), quinolonic acid [QA, a N-methyl D-aspartate receptor (NMDAR) agonist] and kynurenic acid (KA, an NMDAR antagonist). KYN/TRP…
Abstract Number: 122 • 2020 Pediatric Rheumatology Symposium
Systemic Inflammation and Cognitive Dysfunction in jSLE Patients
Sara Ganhão ¹, Mariana Rodrigues², Beatriz Silva ¹, Francisca Aguiar ¹, Margarida Figueiredo-Braga ¹ and Iva Brito ¹, ¹Centro Hospitalar de São João, Oporto, Portugal, ²Porto, Portugal
Background/Purpose: Neurocognitive dysfunction (NCD) is one of the most commonly reported neuropsychiatric symptoms in patients with juvenile systemic lupus erythematosus (SLE), even without overt CNS…
Abstract Number: 677 • 2019 ACR/ARP Annual Meeting
Performance of Montreal Cognitive Assessment (MoCA) in Screening for Cognitive Impairment in Patients with Lupus Compared to the Neuropsychological Battery
Mahta Kakvan ¹, Robin Green ², Lesley Ruttan ³, Maria Tartaglia ⁴, Joan Wither ⁵, Moe Zandy ¹, Dennisse Bonilla ¹, May Choi ⁶, Jiandong Su ¹, Marvin Fritzler ⁶, Dorcas Beaton ⁷ and Zahi Touma¹, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, Toronto, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷St. Michael's Hospital, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is a common neuropsychological manifestation of Systemic Lupus Erythematosus (SLE) with a prevalence of 38% [95% confidence interval: 33,43%]. Previous studies,…
Abstract Number: 1612 • 2019 ACR/ARP Annual Meeting
Disease Activity and Cognitive Function in Systemic Lupus Erythematosus
Michelle Barraclough ¹, Shane McKie ², Benjamin Parker ¹, Alan Jackson ³, Philip Pemberton ⁴, Rebecca Elliott ⁵ and Ian Bruce⁶, ¹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²FBMH Platform Sciences, Enabling Technologies & Infrastructure, The University of Manchester, Manchester, United Kingdom, ³Wolfson Molecular Imaging Centre, Institute of imaging and bioinformatics, The University of Manchester, Manchester, United Kingdom, ⁴Manchester University NHS Foundation Trust, Manchester, ⁵Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom
Background/Purpose: Cognitive dysfunction (CD) is a common symptom in systemic lupus erythematosus (SLE), that significantly affects quality of life but there are limited treatment options…
Abstract Number: 1792 • 2019 ACR/ARP Annual Meeting
Cognitive Dysfunction (CD) and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Primary Antiphospholipid Syndrome (PAPS)
Renata Rosa¹, Michelle Remião Ugolini-Lopes ², Ana Paula Gandara ², Kenia Campanholo ², Livia Dutra ³ and Danieli Andrade ⁴, ¹Faculdade de Medicina da Universidade de São Paulo (USP), Brazil., São Paulo, Sao Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo (USP), Brazil., São Paulo, Brazil, ³Escola Paulista de Medicina (EPM), Brazil, São Paulo, Brazil, ⁴Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: Cognition dysfunction (CD) is a poorly understood non-stroke central neurologic manifestation of antiphospholipid syndrome, whose diagnosis involves a specific neuropsychological (NP) evaluation. Brain-derived neurotrophic…
Abstract Number: 1667 • 2018 ACR/ARHP Annual Meeting
Confirmatory Factor Analysis of the Patient-Reported Perceived Deficits Questionnaire in Systemic Lupus Erythematosus: Cautions for Use of Subscales
Lisa Engel¹, Jiandong Su¹, Emily Nalder², Yael Goverover³, Monique Gignac⁴, Carmela Tartaglia⁵, Nicole Anderson¹ and Zahi Touma¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Occupational Science and Occupational Therapy, University of Toronto, Toronto, ON, Canada, ³Department of Occupational Therapy, New York University, New York, NY, ⁴Instititue for Work and Health, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada
Background/Purpose: Approximately 38% of adults living with Systemic Lupus Erythematosus (SLE) experience cognitive impairment (CI) that can detrimentally affect employment, disease self-management, and quality of…
Abstract Number: 1941 • 2018 ACR/ARHP Annual Meeting
Altered Cognitive Function in Systemic Lupus Erythematosus and Associations with Inflammation and Functional Brain Changes
Michelle Barraclough^1,2, Rebecca Elliott^2,3, Benjamin Parker^4,5, Shane McKie^2,3, Alan Jackson⁶, Philip Pemberton⁷ and Ian N. Bruce^2,4, ¹The University of Manchester, Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, United Kingdom, ²NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³The University of Manchester, Division of Neuroscience & Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, United Kingdom, ⁴Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁶Imaging Sciences, Wolfson Molecular Imaging Centre, The University of Manchester, Manchester, United Kingdom, ⁷Department of Clinical Biochemistry, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: Cognitive dysfunction is a common problem in systemic lupus erythematosus (SLE) but the cause is still unclear; measuring it can be difficult and, as…
Abstract Number: 2986 • 2018 ACR/ARHP Annual Meeting
The Impact of Exercise and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study
Nancy A. Shadick¹, Christine K Iannaccone², Patricia Katz³, Gabriela L. Maica⁴, Jonathan Coblyn⁵, Michael E Weinblatt⁶ and Jing Cui⁷, ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³University of California San Francisco, San Francisco, CA, ⁴Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Department of Rheumatology, Brigham & Womens Hospital, Boston, MA, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Modifiable lifestyle factors such as inactivity and obesity contribute to cognitive decline in the general population, but little is known about how these factors…
Abstract Number: 259 • 2018 ACR/ARHP Annual Meeting
Prevalence of Attention Deficit Hyperactivity Disorder Among Patients with Fibromyalgia
Sebastian Moyano¹, Waleska Berrios², Ignacio Javier Gandino³, Angel Golimstok⁴, Javier Rosa⁵ and Enrique R Soriano⁶, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Memory and Behavior Disorders Unit - Neurology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina, ⁴Memory and Behavior Disorders Unit - Neurology Department, Hospital Italiano, Buenos Aires, Argentina, ⁵Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ⁶Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina
Background/Purpose: Chronic diseases involve cognitive aspects. Attention deficit hyperactivity disorder (ADHD) is a chronic condition, marked by persistent inattention, impaired concentration, hyperactivity, impulsivity, emotional lability,…
Abstract Number: 409 • 2018 ACR/ARHP Annual Meeting
Unique Skeletal Muscle Relaxant Tolperisone in a Crossover Driving Simulation Study: No Evidence of Sedation Compared to Cyclobenzaprine and Placebo
Judy Caron¹, Thomas Wessel² and Gary Kay³, ¹Drug Development, Neurana Pharmaceuticals, San Diego, CA, ²Medical, Neurana Pharmaceuticals, San Diego, CA, ³Drug Development, Cognitive Research Corporation, St Petersburg, FL
Background/Purpose: Tolperisone is a centrally-acting muscle relaxant being developed in the US as a treatment for acute and painful symptoms of neck and low back…
Abstract Number: 487 • 2018 ACR/ARHP Annual Meeting
Cognitive Impairment in Rheumatoid Arthritis Patients: A Case-Control Study
Beatriz Rizkallah Alves¹, BRUNO KUSZNIR VITTURI², BRUNO AZEREDO COUTINHO NASCIMENTO³, FELIPE SOBOLEWSKI CARNEIRO DE CAMPOS³ and Dawton Yukito Torigoe³, ¹rheumatology, Faculdade de Ciências Médicas da Santa Casa de São Paulo, Sao Paulo, Brazil, ²rheumatology, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brazil, ³Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brazil
Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. Extra-articular manifestations of RA can occur in about 40% of patients, either…
Abstract Number: 723 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Cognitive Screen Does Not Identify Cognitive Sub-Domains: Exploration of the Subscale Structure of the Perceived Deficits Questionnaire in a Systemic Lupus Erythematosus Cohort
Lisa Engel¹, Jiandong Su¹, Emily Nalder², Yael Goverover³, Monique Gignac⁴, Carmela Tartaglia⁵, Nicole Anderson¹ and Zahi Touma¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Occupational Science and Occupational Therapy, University of Toronto, Toronto, ON, Canada, ³Department of Occupational Therapy, New York University, New York, NY, ⁴Instititue for Work and Health, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada
Background/Purpose: Identifying patients with Systemic Lupus Erythematosus related cognitive impairment (SLE-CI) is critical as SLE-CI can negatively affect employment, quality of life, and disease self-management.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].